Van Echo D A, Diggs C H, Scoltock M, Wiernik P H
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):339-42.
N-(Phosphonacetyl)-L-aspartic acid (PALA) was administered at a dose of 1.5 g/m2/day x 5 days in a phase II evaluation of 21 patients with metastatic adenocarcinoma of the colon or rectum. Courses were repeated every 3 weeks. No responses were seen, but 11 patients had disease stabilization. PALA toxicity was marked, causing discontinuation of therapy in two patients. Major toxicity was cutaneous (90%), mucosal (35%), and gastrointestinal (diarrhea, at times bloody) (50%). There was no evidence of myelosuppression or CNS toxicity. PALA appears inactive in patients with metastatic colorectal carcinoma in the dose and schedule used in this study.
在对21例结肠或直肠转移性腺癌患者进行的II期评估中，以1.5 g/m²/天的剂量给予N-（膦酰乙酰基）-L-天冬氨酸（PALA），持续5天。每3周重复疗程。未观察到缓解，但有11例患者病情稳定。PALA毒性显著，导致2例患者停止治疗。主要毒性为皮肤毒性（90%）、粘膜毒性（35%）和胃肠道毒性（腹泻，有时带血）（50%）。没有骨髓抑制或中枢神经系统毒性的证据。在本研究使用的剂量和疗程下，PALA对转移性结直肠癌患者似乎无活性。
Zotero 插件